Boston Scientific Co. (NYSE:BSX) EVP Sells $5,799,551.36 in Stock

Boston Scientific Co. (NYSE:BSX - Get Free Report) EVP Joseph Michael Fitzgerald sold 56,372 shares of the company's stock in a transaction that occurred on Wednesday, June 4th. The shares were sold at an average price of $102.88, for a total transaction of $5,799,551.36. Following the transaction, the executive vice president now directly owns 178,342 shares in the company, valued at $18,347,824.96. The trade was a 24.02% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link.

Boston Scientific Stock Performance

Shares of BSX traded down $0.79 during mid-day trading on Friday, reaching $102.04. 9,113,579 shares of the company's stock traded hands, compared to its average volume of 6,465,789. Boston Scientific Co. has a 12 month low of $71.88 and a 12 month high of $107.17. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.02 and a current ratio of 1.08. The stock has a market capitalization of $150.96 billion, a P/E ratio of 81.63, a price-to-earnings-growth ratio of 2.79 and a beta of 0.68. The business's 50-day moving average price is $100.47 and its 200-day moving average price is $98.29.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.08. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. The company had revenue of $4.66 billion during the quarter, compared to analysts' expectations of $4.57 billion. During the same quarter in the prior year, the business posted $0.56 earnings per share. The company's revenue for the quarter was up 20.9% compared to the same quarter last year. Equities analysts predict that Boston Scientific Co. will post 2.85 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on BSX shares. Argus set a $130.00 target price on shares of Boston Scientific in a report on Tuesday, February 18th. Raymond James boosted their price objective on shares of Boston Scientific from $119.00 to $122.00 and gave the company a "strong-buy" rating in a research note on Thursday, February 6th. Truist Financial lifted their target price on Boston Scientific from $113.00 to $117.00 and gave the company a "buy" rating in a report on Thursday, April 24th. Needham & Company LLC restated a "buy" rating and set a $115.00 price target on shares of Boston Scientific in a research note on Wednesday, May 28th. Finally, Morgan Stanley raised their price target on shares of Boston Scientific from $120.00 to $125.00 and gave the company an "overweight" rating in a report on Friday, May 16th. Twenty-one analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of "Buy" and an average price target of $116.00.

Hedge Funds Weigh In On Boston Scientific

Several large investors have recently bought and sold shares of BSX. 1248 Management LLC bought a new stake in Boston Scientific during the first quarter worth approximately $26,000. Y.D. More Investments Ltd bought a new position in Boston Scientific during the 1st quarter valued at $27,000. Investment Management Corp VA ADV bought a new stake in shares of Boston Scientific in the 4th quarter worth $25,000. Colonial Trust Co SC lifted its holdings in shares of Boston Scientific by 1,625.0% in the fourth quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider's stock valued at $25,000 after buying an additional 260 shares during the period. Finally, TFC Financial Management Inc. boosted its stake in Boston Scientific by 308.8% during the fourth quarter. TFC Financial Management Inc. now owns 278 shares of the medical equipment provider's stock valued at $25,000 after buying an additional 210 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company's stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.